Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) FCF Margin (2016 - 2025)

Historic FCF Margin for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to 1526.54%.

  • Fate Therapeutics' FCF Margin fell 5534100.0% to 1526.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 1617.32%, marking a year-over-year decrease of 6317800.0%. This contributed to the annual value of 906.79% for FY2024, which is 6889200.0% down from last year.
  • Per Fate Therapeutics' latest filing, its FCF Margin stood at 1526.54% for Q3 2025, which was down 5534100.0% from 1360.72% recorded in Q2 2025.
  • Over the past 5 years, Fate Therapeutics' FCF Margin peaked at 54.37% during Q1 2023, and registered a low of 3289.6% during Q2 2023.
  • Its 5-year average for FCF Margin is 1057.74%, with a median of 519.43% in 2021.
  • As far as peak fluctuations go, Fate Therapeutics' FCF Margin plummeted by -29484100bps in 2023, and later surged by 28118000bps in 2024.
  • Over the past 5 years, Fate Therapeutics' FCF Margin (Quarter) stood at 519.43% in 2021, then skyrocketed by 64bps to 185.02% in 2022, then tumbled by -1087bps to 2196.78% in 2023, then surged by 32bps to 1499.84% in 2024, then dropped by -2bps to 1526.54% in 2025.
  • Its FCF Margin was 1526.54% in Q3 2025, compared to 1360.72% in Q2 2025 and 2148.86% in Q1 2025.